Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 767Lung Neoplasms 340Ovarian Neoplasms 318Breast Neoplasms 277Fallopian Tube Neoplasms 158Triple Negative Breast Neoplasms 144Small Cell Lung Carcinoma 142Neoplasms 134Squamous Cell Carcinoma of Head and Neck 122Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 77Esophageal Neoplasms 71Uterine Cervical Neoplasms 70Adenocarcinoma of Lung 69Neuroblastoma 55Central Nervous System Neoplasms 52Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Brain Neoplasms 48Recurrence 47Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Lymphoma, Non-Hodgkin 31

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nonsquamous Non-small Cell Lung Cancer × Carboplatin × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡